Revvity (NYSE:RVTY) Price Target Lowered to $125.00 at The Goldman Sachs Group

Revvity (NYSE:RVTY) had its target price cut by equities researchers at The Goldman Sachs Group from $140.00 to $125.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s price objective suggests a potential upside of 33.92% from the company’s current price.

Other research analysts also recently issued reports about the company. JPMorgan Chase & Co. dropped their target price on Revvity from $120.00 to $100.00 and set a “neutral” rating on the stock in a research note on Tuesday. KeyCorp upped their price objective on shares of Revvity from $132.00 to $145.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. Robert W. Baird dropped their target price on shares of Revvity from $127.00 to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday. Wells Fargo & Company decreased their target price on Revvity from $130.00 to $102.00 and set an “equal weight” rating for the company in a report on Thursday, April 17th. Finally, Barclays decreased their target price on shares of Revvity from $140.00 to $110.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $126.46.

Revvity Stock Performance

RVTY stock opened at $93.34 on Tuesday. Revvity has a one year low of $88.53 and a one year high of $129.50. The firm has a market cap of $11.21 billion, a price-to-earnings ratio of 42.24, a PEG ratio of 3.82 and a beta of 1.07. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The firm has a 50-day simple moving average of $103.67 and a two-hundred day simple moving average of $112.54.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, April 28th. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. The company had revenue of $664.76 million during the quarter, compared to analysts’ expectations of $662.30 million. During the same quarter in the prior year, the company posted $0.98 earnings per share. Revvity’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, equities analysts forecast that Revvity will post 4.94 EPS for the current fiscal year.

Institutional Trading of Revvity

Several large investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. raised its stake in Revvity by 16.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 20,761,308 shares of the company’s stock worth $2,317,170,000 after purchasing an additional 2,969,326 shares during the period. EdgePoint Investment Group Inc. lifted its holdings in Revvity by 51.1% in the fourth quarter. EdgePoint Investment Group Inc. now owns 4,058,231 shares of the company’s stock valued at $452,939,000 after acquiring an additional 1,372,456 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Revvity by 17.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,631,597 shares of the company’s stock worth $851,764,000 after acquiring an additional 1,151,821 shares during the period. Norges Bank acquired a new stake in Revvity during the fourth quarter worth $127,801,000. Finally, GAMMA Investing LLC raised its position in Revvity by 15,023.0% in the first quarter. GAMMA Investing LLC now owns 287,035 shares of the company’s stock valued at $30,368,000 after purchasing an additional 285,137 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.